EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: There are already several examples of such personalized treatments including the drug Gleevec that targets the BCR-ABL fusion gene in chronic myelogenous leukemia (CML) and Iressa that targets the EGFR gene in lung cancer.